Furthermore, it is demonstrated that PBRM1 can impede iCCA progression, and a gene therapy nanomedicine is developed to treat iCCA in vivo by modulating PBRM1 expression. This evidence concerns the gene PBRM1 and infantile convulsions and choreoathetosis.